| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.1 | 0.0 |
| Gross profit | 0.0 | 0.0 |
| Profit before tax | -3.2 | -4.6 |
| Net income | -3.2 | -4.6 |
| EPS (diluted, $ a share) | $-2.83 | $-12.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +255.4% |
|---|---|
| Gross margin | 50.7% |
10-Q filed with the SEC, NASDAQ: HCWB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
HCW Biologics Inc.: key numbers
- Share price
- $0.7767Close, Nov 17
- Market cap
- $2.44M
- Shares outstanding
- 3.14MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from HCW Biologics Inc.
All →HCW Biologics Financial Results
HCW Biologics reported financial results for the third quarter of 2026, highlighting progress in its HCW9302 Phase 1 clinical study for alopecia areata and the presentation of its TRBC platform molecules at SITC2026. The company recently secured up to $10.0 million in debt financing to support its clinical and preclinical programs through the Phase 1 readout expected in Q1 2027.
- Term
- Q3 2026
“Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases.”
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer
HCW Biologics $10.2M Debt Financing with Streeterville Capital, LLC
HCW Biologics entered into a Notes Purchase Agreement for the issuance of two secured promissory notes totaling $10.2 million in principal ($3.2M A-1 Note and $7.0M B Note). The financing provides immediate net proceeds of approximately $3.0 million, with the remaining $7.0 million held in a restricted account to be released as the A-1 Note is repaid. Proceeds will fund the Phase 1 clinical study of HCW9302 for alopecia areata through its expected readout in Q1 2027.
- Value
- $10.2M
- Counterparty
- Streeterville Capital, LLC
- Term
- 24 months
HCW Biologics Capital Raise of $1.5M
HCW Biologics entered into a securities purchase agreement with an institutional investor to raise approximately $1.5 million through the sale of 903,614 units. Each unit consists of a pre-funded warrant and a common stock purchase warrant, with proceeds intended for working capital and clinical development activities.
- Value
- $1.5M
- Counterparty
- institutional investor